This study introduces a system for predicting disease progression events in multiple myeloma patients from the CoMMpass study (=1186). Utilizing a hybrid neural network architecture, our model predicts future blood work from historical lab results with high accuracy, significantly outperforming baseline ...
Plasma cells are white blood cells that are part of the immune system. They produce antibodies, also known as immunoglobulins, to help fight infection. In myeloma, plasma cells become abnormal and transform into cancerous myeloma cells. As they multiply, they crowd out and interfere with producti...
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells. In patients with MM, there are abnormalities ...
Multiple Myeloma. Multiple myeloma(MM) is a rare, malignant tumor of plasma cells that arises in the bone marrow and usually secretes large amounts ofimmunoglobulin. The finding of neoplastic plasma cells in blood samples or smears is rare.Dogsare affected more frequently than other species, but...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] MM is part of a spectrum of diseases ...
How Does Multiple Myeloma Affect Your Bones? Multiple myeloma is a blood cancer that occurs when white blood cells, called plasma cells, increase out of control in the bones. Myeloma destroys the bone by making osteoclasts – cells that break down old bones – become more active and weaken yo...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and acute kidney injury. In approximately 30% of cases, MM is discovered through routine blood screening when patient...
Multiple myeloma (MM) is a biologically and clinically heterogeneous malignancy of terminally differentiated plasma cells (PCs), which abnormally proliferate in the bone marrow (BM), and typically secrete non-functional monoclonal immunoglobulin (Ig) in serum and urine. The stages of MM development us...
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells.
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma, characterized by the ability of a subclone to thrive and grow independent of the bone marrow microenvironment, resulting in a high-risk state associated with increased